Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
07
2022
accepted:
14
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
1
11
2022
Statut:
epublish
Résumé
Liver fibrosis is one of the cardinal clinical features of chronic hepatitis C (CHC). However, the mechanisms underlying the evolution and reversion of liver fibrosis after hepatitis C virus (HCV) eradication and their relationship with clinical outcomes and metabolic alterations are not fully elucidated. Whether any non-invasive fibrosis marker can predict prognosis is unknown. Between October 2014 and September 2019, 418 patients with CHC or compensated cirrhosis with HCV were prospectively recruited in this observational study. 326 patients that were successfully eradicated with interferon-free direct antiviral agents (IFN-free DAAs) were analyzed. Peri-treatment dynamics of serum levels of type IV collagen 7S fragment (4COL7S), a fibrosis marker, and subsequent clinical outcomes, including hepatic decompensation, newly emerged hepatocellular carcinoma (HCC), and all-cause mortality were analyzed. Ten (3.1%) patients died during the observation period. 4COL7S-defined fibrosis progression (n = 97, 29.8%) at SVR was significantly correlated with worse all-cause mortality post-SVR (P = 0.0062) but not with the probability of newly emerged HCC (P = 0.24). Prognostic tendency was more prominent in patients with advanced fibrosis (P< 0.0001). 4COL7S-defined fibrosis progression at SVR and a baseline platelet count less than 10×104/μL were significantly predicted all-cause mortality (P = 0.0051). In exploratory analyses, a decreased 4COL7S at the end of treatment was correlated with a matrix-degrading phenotype that showed higher serum metalloproteinase to tissue inhibitors of metalloproteinase-1 ratios and characteristic metabolic fingerprints such as increased butyrate, some medium-chain fatty acids, anabolic amino acids, and decreased uremia toxins. Peri-treatment dynamics of serum 4COL7S, a non-invasive fibrosis marker, predict prognosis. Non-invasive fibrosis markers may be useful biomarkers for risk stratification post-SVR.
Sections du résumé
BACKGROUND
Liver fibrosis is one of the cardinal clinical features of chronic hepatitis C (CHC). However, the mechanisms underlying the evolution and reversion of liver fibrosis after hepatitis C virus (HCV) eradication and their relationship with clinical outcomes and metabolic alterations are not fully elucidated. Whether any non-invasive fibrosis marker can predict prognosis is unknown.
METHODS
Between October 2014 and September 2019, 418 patients with CHC or compensated cirrhosis with HCV were prospectively recruited in this observational study. 326 patients that were successfully eradicated with interferon-free direct antiviral agents (IFN-free DAAs) were analyzed. Peri-treatment dynamics of serum levels of type IV collagen 7S fragment (4COL7S), a fibrosis marker, and subsequent clinical outcomes, including hepatic decompensation, newly emerged hepatocellular carcinoma (HCC), and all-cause mortality were analyzed.
RESULTS
Ten (3.1%) patients died during the observation period. 4COL7S-defined fibrosis progression (n = 97, 29.8%) at SVR was significantly correlated with worse all-cause mortality post-SVR (P = 0.0062) but not with the probability of newly emerged HCC (P = 0.24). Prognostic tendency was more prominent in patients with advanced fibrosis (P< 0.0001). 4COL7S-defined fibrosis progression at SVR and a baseline platelet count less than 10×104/μL were significantly predicted all-cause mortality (P = 0.0051). In exploratory analyses, a decreased 4COL7S at the end of treatment was correlated with a matrix-degrading phenotype that showed higher serum metalloproteinase to tissue inhibitors of metalloproteinase-1 ratios and characteristic metabolic fingerprints such as increased butyrate, some medium-chain fatty acids, anabolic amino acids, and decreased uremia toxins.
CONCLUSIONS
Peri-treatment dynamics of serum 4COL7S, a non-invasive fibrosis marker, predict prognosis. Non-invasive fibrosis markers may be useful biomarkers for risk stratification post-SVR.
Identifiants
pubmed: 36301899
doi: 10.1371/journal.pone.0276925
pii: PONE-D-22-21128
pmc: PMC9612469
doi:
Substances chimiques
Antiviral Agents
0
Collagen Type IV
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0276925Déclaration de conflit d'intérêts
Y.K. is an employee at Mitsubishi Tanabe Pharma Corporation. The remaining authors declare no competing interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
FASEB J. 2006 Mar;20(3):444-54
pubmed: 16507762
Hepatol Commun. 2018 Sep 21;2(11):1331-1343
pubmed: 30411080
Gastroenterology. 2021 Apr;160(5):1502-1520.e1
pubmed: 33529675
Mol Biosyst. 2008 Feb;4(2):135-47
pubmed: 18213407
PLoS One. 2014 Apr 09;9(4):e94460
pubmed: 24718268
Hepatol Res. 2012 May;42(5):482-93
pubmed: 22221767
J Am Soc Nephrol. 2012 Jul;23(7):1258-70
pubmed: 22626821
J Hepatol. 2020 Aug;73(2):277-284
pubmed: 32145260
Hepatology. 2002 Oct;36(4 Pt 1):986-92
pubmed: 12297848
Clin Infect Dis. 2020 Dec 3;71(9):2354-2362
pubmed: 31754695
Metabolism. 1995 May;44(5):584-8
pubmed: 7752905
J Hepatol. 2007 May;46(5):955-75
pubmed: 17383048
Gastroenterology. 2019 Oct;157(4):1055-1066.e11
pubmed: 31251928
Hepatology. 2005 Jun;41(6):1376-82
pubmed: 15915455
Sci Rep. 2019 Nov 5;9(1):16062
pubmed: 31690732
Hepatology. 2016 Jul;64(1):130-7
pubmed: 26946190
Int J Cardiol. 2017 Jun 1;236:483-487
pubmed: 28109578
J Hepatol. 2013 Oct;59(4):675-83
pubmed: 23712051
Viruses. 2021 Nov 09;13(11):
pubmed: 34835054
J Hepatol. 2003;38 Suppl 1:S38-53
pubmed: 12591185
Medicine (Baltimore). 2017 May;96(18):e6617
pubmed: 28471958
Lancet. 2019 Apr 6;393(10179):1453-1464
pubmed: 30765123
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Aliment Pharmacol Ther. 2018 Dec;48(11-12):1301-1311
pubmed: 30345704
PLoS One. 2018 Mar 13;13(3):e0194163
pubmed: 29534101
Hepatology. 2012 Aug;56(2):532-43
pubmed: 22271347
Gastroenterology. 2015 Nov;149(6):1345-60
pubmed: 26319013
J Gastroenterol. 2020 Oct;55(10):990-999
pubmed: 32770465
Gastroenterology. 2019 Aug;157(2):537-551.e9
pubmed: 30978357
Clin Gastroenterol Hepatol. 2016 Jul;14(7):1044-1055.e3
pubmed: 26804385
Hepatology. 2013 Oct;58(4):1253-62
pubmed: 23564522
J Am Heart Assoc. 2018 Nov 6;7(21):e009193
pubmed: 30608207
Hepatol Commun. 2020 Nov 16;5(4):559-572
pubmed: 33860115
J Clin Exp Hepatol. 2021 Mar-Apr;11(2):195-200
pubmed: 33746444
Hepatology. 2019 Feb;69(2):487-497
pubmed: 28749564
Chest. 2018 Oct;154(4):798-807
pubmed: 29966667
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
J Hepatol. 2018 Apr;68(4):699-706
pubmed: 29191459
Biochim Biophys Acta. 2013 Jul;1832(7):876-83
pubmed: 23149387
J Hepatol. 1999 Jan;30(1):48-60
pubmed: 9927150
J Hepatol. 2021 Jan;74(1):37-47
pubmed: 32798585
Gastroenterology. 2019 Jan;156(2):446-460.e2
pubmed: 30367836
J Hepatol. 2021 Sep;75(3):659-689
pubmed: 34166721
Gastroenterology. 2019 Nov;157(5):1264-1278.e4
pubmed: 31356807
PLoS One. 2021 Sep 10;16(9):e0257166
pubmed: 34506563
J Hepatol. 1996 Feb;24(2):148-54
pubmed: 8907567
Hepatol Res. 2019 Oct;49(10):1109-1113
pubmed: 31336394
BMC Gastroenterol. 2018 Jul 11;18(1):112
pubmed: 29996772
Hepatology. 2008 Aug;48(2):418-31
pubmed: 18563841
Hepatology. 2020 Nov;72(5):1605-1616
pubmed: 32043613
N Engl J Med. 2011 Jun 23;364(25):2429-38
pubmed: 21696309
Metabolomics. 2010 Mar;6(1):78-95
pubmed: 20300169